title: Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
abstract: METHODS
  Nine public health care centres in four Spanish cities.
  
  
  OBJECTIVE
  To evaluate the efficacy and safety of 2 months of rifampicin (R) plus pyrazinamide (Z) therapy (2RZ) compared with a 6-month course of isoniazid therapy (6H) for treating latent tuberculosis infection (LTBI).
  
  
  METHODS
  Multicentered, randomised, comparative and prospective trial conducted in HIV-seronegative contacts of infectious pulmonary TB cases.
  
  
  RESULTS
  Of 352 individuals, 199 received 6H and 153 2RZ; 73% of contacts receiving 6H and 71% receiving 2RZ completed treatment (P = 0.73). Treatment interruption due to hepatotoxicity (ALT/AST > 5 times upper limit of normal) was observed in 10% of contacts in the 2RZ group and in 2.5% of the 6H group (P = 0.007). This higher than expected rate of hepatotoxicity in the 2RZ arm led to premature termination of the study. Severe or fatal liver injury was not detected. Liver function tests normalised after discontinuation of treatment. We conclude that the use of RZ should only be considered when other regimens are unsuitable and intensive monitoring of liver function is feasible.
authors.affiliation: Departmento de Epidemiologia, Agència de Salut Pública de Barcelona, Barcelona. ctortaja@imsb.bcn.es
authors.forename: C
authors.initials: C
authors.lastname: Tortajada
authors.forename: J
authors.initials: J
authors.lastname: Martínez-Lacasa
authors.forename: F
authors.initials: F
authors.lastname: Sánchez
authors.forename: A
authors.initials: A
authors.lastname: Jiménez-Fuentes
authors.forename: M L
authors.initials: ML
authors.lastname: De Souza
authors.forename: J F
authors.initials: JF
authors.lastname: García
authors.forename: J A
authors.initials: JA
authors.lastname: Martínez
authors.forename: J A
authors.initials: JA
authors.lastname: Caylà
mesh_terms: D000293:Adolescent; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology; D018023:HIV Seronegativity; D006801:Humans; D007223:Infant; D008297:Male; D011446:Prospective Studies; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D013030:Spain; D016896:Treatment Outcome; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000904:Antibiotics, Antitubercular; D015483:HIV Antibodies; D011718:Pyrazinamide; D012293:Rifampin